Tag: Watchman FLX
AHA 2024: OPTION trial reports positive outcomes for Watchman FLX at three years after AF ablation
Three-year results from the OPTION clinical trial, comparing the Watchman FLX (Boston Scientific...
Medtech Insights: Trial pipeline underpins growth strategy for Watchman LAAC device
Investment in a programme of clinical trials will underpin Boston Scientific’s strategy to expand th...
CRT 2022: SURPASS registry shows low rate of adverse events associated with Watchman FLX
Results from a new analysis assessing real-world outcomes with the Watchman FLX (Boston Scientif...
Next-generation Watchman LAAC device gains US FDA approval
Boston Scientific has received US Food and Drug Administration (FDA) approval for the Watchman F...
Boston Scientific announces schedule of presentations at TCT 2019
Boston Scientific has announced the key data that will be presented at the Transcatheter Cardiov...
New trial to compare Watchman FLX to direct oral anticoagulants
The OPTION trial is to compare the compare safety and effectiveness of the next-generation Watch...
